Lauritzsen G F, Hofgaard P O, Schenck K, Bogen B
Institute of Immunology and Rheumatology, University of Oslo, Norway.
Int J Cancer. 1998 Oct 5;78(2):216-22. doi: 10.1002/(sici)1097-0215(19981005)78:2<216::aid-ijc16>3.0.co;2-8.
Clonal deletion of thymocytes is a major event in T-cell tolerance and might represent a tumor escape mechanism. Previously, we have shown that class II-restricted, Id-specific, CD4+ T cells in T-cell receptor (TCR)-transgenic mice confer resistance against the MOPC315 plasmacytoma. In this report, we have investigated whether monoclonal immunoglobulin (Ig) produced by a plasmacytoma can induce deletion of thymocytes specific for the variable parts of Ig, i.e., the idiotype (Id). Large numbers of MOPC315 tumor cells were injected s.c. in the TCR-transgenic mice to overwhelm the CD4+ T-cell-mediated protection. When the MOPC315 plasmacytomas reached a weight of approximately 0.5 g (serum myeloma protein M315 about 50 microg/ml), immature CD4+ 8+ and mature CD4+ transgenic thymocytes became progressively deleted. Apoptotic thymocytes were already detectable when tumors were 2 mm in diameter (serum M315: 5 microg/ml, or 0.03 microM). The negative selection was Id-specific, because an Id-negative plasmacytoma failed to induce deletion. Injection of purified MOPC315-myeloma protein (M315) i.p. caused a profound reduction of Id-specific thymocytes. Enriched thymic dendritic cells (DC) from tumor-bearing animals were found to be primed with lambda2(315) and induced apoptosis of thymocytes in vitro. Our results indicate that circulating myeloma protein is processed and presented by thymic antigen-presenting cells (APC), and induces deletion of Id-specific thymocytes. Deletion of tumor-specific thymocytes may represent a tumor escape mechanism in patients with cancers that secrete or shed tumor antigens. The possibility that vaccination with tumor Ig or genes encoding for it may induce tolerance instead of protection should be taken into consideration.
胸腺细胞的克隆清除是T细胞耐受中的一个主要事件,可能代表一种肿瘤逃逸机制。此前,我们已经表明,在T细胞受体(TCR)转基因小鼠中,II类限制性、Id特异性的CD4⁺ T细胞赋予了对MOPC315浆细胞瘤的抗性。在本报告中,我们研究了浆细胞瘤产生的单克隆免疫球蛋白(Ig)是否能诱导对Ig可变部分特异的胸腺细胞的清除,并将其命名为独特型(Id)。将大量MOPC315肿瘤细胞皮下注射到TCR转基因小鼠中,以克服CD4⁺ T细胞介导的保护作用。当MOPC315浆细胞瘤达到约0.5 g的重量时(血清骨髓瘤蛋白M315约为50 μg/ml),未成熟的CD4⁺8⁺ 和成熟的CD4⁺转基因胸腺细胞逐渐被清除。当肿瘤直径为2 mm时(血清M315:5 μg/ml,或0.03 μM),凋亡的胸腺细胞就已经可以检测到。阴性选择是Id特异性的,因为Id阴性的浆细胞瘤未能诱导清除。腹腔注射纯化的MOPC315骨髓瘤蛋白(M315)导致Id特异性胸腺细胞显著减少。发现来自荷瘤动物的富集胸腺树突状细胞(DC)被λ2(315)致敏,并在体外诱导胸腺细胞凋亡。我们的结果表明,循环中的骨髓瘤蛋白被胸腺抗原呈递细胞(APC)加工并呈递,并诱导Id特异性胸腺细胞的清除。肿瘤特异性胸腺细胞的清除可能代表了分泌或释放肿瘤抗原的癌症患者中的一种肿瘤逃逸机制。应考虑到用肿瘤Ig或其编码基因进行疫苗接种可能诱导耐受而非保护的可能性。